Patient-derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas.

Purpose: Identifying therapeutic targets for Signet Ring Cell Carcinoma (SRCC) of the colon and rectum is a clinical challenge due to the lack of Patient-Derived Organoids (PDO) or Xenografts (PDX). We present a robust method to establish PDO and PDX models to answer address this unmet need. We demonstrate that these models identify novel therapeutic strategies targeting therapy resistance and peritoneal metastasis.

First report of Anaplasma marginale and Anaplasma ovis in goats in Kelantan, Malaysia.

Anaplasma species are obligate rickettsial intraerythrocytic pathogens that cause an important tick-borne disease of economic importance in livestock production in many countries. Anaplasma species have been detected from farm animals worldwide, there is a paucity of information on Anaplasma infections in goats from Malaysia. Thus, this study aimed to assess the infection rate and identify Anaplasma species and some selected risk factors in goats across selected districts in Kelantan, Malaysia.

Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer.

A significant clinical challenge in patients with colorectal cancer (CRC), which adversely impacts patient survival, is the development of therapy resistance leading to a relapse. Therapy resistance and relapse in CRC is associated with the formation of lipid droplets (LD) by stimulating de novo lipogenesis (DNL). However, the molecular mechanisms underlying the increase in DNL and the susceptibility to DNL-targeted therapies remain unclear.

Synthesis and Evaluation of Antidiabetic Potential of Gliptin-based Hybrid Scaffolds.

Dipeptidyl peptidase-4 (DPP4) inhibitors are promising therapeutic targets for the treatment of a catastrophic disease, especially diabetes mellitus (DM), which contributed to a massive rate of mortality. This research work succinctly covers the significance and vital role of gliptins in diabetes management and in the potential areas of further antidiabetic research, making it a strong drug candidate for antidiabetic drug development. We illustrated herein molecular docking, synthesis, and biological evaluation of selected potent synthesized molecules.